In the first trial, the executives of the manufacturing distribution company were convicted of manipulating the ingredients of Invossa, a gene treatment for osteoarthritis, and filing false documents to the authorities.
The 25th Department of the Seoul Central District Court's Criminal Agreement convicted Moo Jo, director of Kolon Life Sciences, and Moo Kim, director of the Kolon Bio New Drug Research Institute, for not having enough evidence.
However, in the case of Mr. Jo, he was convicted of handing over 2 million won to a KFDA official in the process of developing Invossa, and was sentenced to a fine of 5 million won.
Whether to resume production and distribution of Invossa, which was suspended due to the cancellation of the product license from the Ministry of Food and Drug Safety, is decided at the Seoul Administrative Court at 3 pm today (19th).